Bristol-Myers, Five Prime Expand Work on Cancer, Other Drugs Print E-mail
By Linda A. Johnson - AP   
Thursday, 15 October 2015 20:08
Drugmaker Bristol-Myers Squibb Co. is expanding its collaboration with Five Prime Therapeutics Inc., which could receive more than $1.75 billion if they succeed in turning Five Prime's antibody-based drug candidates into approved medicines for cancer and immune-system disorders.
      
The key goal is to develop combinations of drugs from the two companies that are more effective together than separately, particularly in the hot new field of immuno-oncology.
    
New York-based Bristol-Myers will gain exclusive worldwide rights to resulting drugs by taking over all costs of testing, applying for regulatory approval and marketing. It's also adding development of drugs for rheumatoid arthritis and a rare, sometimes life-threatening joint disorder called PVNS to the deal.
    
Bristol-Myers has a slight, early lead over rivals including Merck & Co. in developing immuno-oncology drugs. Subcategories of such drugs use different mechanisms to stimulate the body's immune system to spot and attack tumor cells that otherwise could "cloak" themselves, dampening the immune system's ability to fight off cancer.
    
Five Prime is creating drugs, including one known as FPA008 that's in the first round of patient testing, that work by preventing tumor cells from co-opting immune cells called macrophages so they can't kill the tumor cells.
  
  



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter